Dianthus Therapeutics Highlights Claseprubart Data Presentations Planned for 2026 AANEM Annual Meeting Press Release
American Association of Neuromuscular and Electrodiagnostic Medicine (AANEM) Annual Meeting September 29, 2026 CAPTIVATE Interim Analysis: A Pivotal Phase 3 Study of Claseprubart in Chronic Inflammatory Demyelinating Polyneuropathy (poster) 1.5 MB American Association of Neuromuscular and Electrodiagnostic Medicine (AANEM) Annual Meeting September 29, 2026 Upstream Versus Downstream Complement Blockade: Potential Mechanistic Advantages of aC1s Targeting in Myasthenia Gravis 1.4 MB American Association of Neuromuscular and Electrodiagnostic Medicine (AANEM) Annual Meeting September 29, 2026 CAPTIVATE Interim Analysis: A Pivotal Phase 3 Study of Claseprubart in Chronic Inflammatory Demyelinating Polyneuropathy (slides) 579 KB American Association of Neuromuscular and Electrodiagnostic Medicine (AANEM) Annual Meeting September 29, 2026 Minimal Symptom Expression with Claseprubart, an Active C1s Inhibitor, in Patients with Generalized Myasthenia Gravis 1.4 MB American Association of Neuromuscular and Electrodiagnostic Medicine (AANEM) Annual Meeting September 29, 2026 Sustained Safety and Efficacy Profile of Active C1s Inhibitor Claseprubart in Patients with Generalized Myasthenia Gravis 1.3 MB American Academy of Neurology (AAN) Autoimmune Neurology Conference August 7, 2026 Minimal Symptom Expression with Claseprubart, an Active C1s Inhibitor, in Patients with Generalized Myasthenia Gravis 2.7 MB American Academy of Neurology (AAN) Autoimmune Neurology Conference August 7, 2026 Safety and Efficacy of Claseprubart, an Active C1s Inhibitor, in Patients with Generalized Myasthenia Gravis 566.7 KB American Academy of Neurology (AAN) Autoimmune Neurology Conference August 7, 2026 Safety and Efficacy of Claseprubart, an Active C1s Inhibitor, in Patients with Generalized Myasthenia Gravis 2.3 MB American Academy of Neurology (AAN) Autoimmune Neurology Conference August 7, 2026 CAPTIVATE Trial Design: A Pivotal Phase 3 Study of Claseprubart in Chronic Inflammatory Demyelinating Polyneuropathy 2.3 MB American Academy of Neurology (AAN) Autoimmune Neurology Conference August 7, 2026 Potential Mechanistic Advantages of aC1s Targeting in Myasthenia Gravis: Upstream Versus Downstream Complement Blockade 2.7 MB Pagination Current page 1 Page 2 Page 3 … Next page › Last page »
American Association of Neuromuscular and Electrodiagnostic Medicine (AANEM) Annual Meeting September 29, 2026 CAPTIVATE Interim Analysis: A Pivotal Phase 3 Study of Claseprubart in Chronic Inflammatory Demyelinating Polyneuropathy (poster) 1.5 MB
CAPTIVATE Interim Analysis: A Pivotal Phase 3 Study of Claseprubart in Chronic Inflammatory Demyelinating Polyneuropathy (poster) 1.5 MB
American Association of Neuromuscular and Electrodiagnostic Medicine (AANEM) Annual Meeting September 29, 2026 Upstream Versus Downstream Complement Blockade: Potential Mechanistic Advantages of aC1s Targeting in Myasthenia Gravis 1.4 MB
Upstream Versus Downstream Complement Blockade: Potential Mechanistic Advantages of aC1s Targeting in Myasthenia Gravis 1.4 MB
American Association of Neuromuscular and Electrodiagnostic Medicine (AANEM) Annual Meeting September 29, 2026 CAPTIVATE Interim Analysis: A Pivotal Phase 3 Study of Claseprubart in Chronic Inflammatory Demyelinating Polyneuropathy (slides) 579 KB
CAPTIVATE Interim Analysis: A Pivotal Phase 3 Study of Claseprubart in Chronic Inflammatory Demyelinating Polyneuropathy (slides) 579 KB
American Association of Neuromuscular and Electrodiagnostic Medicine (AANEM) Annual Meeting September 29, 2026 Minimal Symptom Expression with Claseprubart, an Active C1s Inhibitor, in Patients with Generalized Myasthenia Gravis 1.4 MB
Minimal Symptom Expression with Claseprubart, an Active C1s Inhibitor, in Patients with Generalized Myasthenia Gravis 1.4 MB
American Association of Neuromuscular and Electrodiagnostic Medicine (AANEM) Annual Meeting September 29, 2026 Sustained Safety and Efficacy Profile of Active C1s Inhibitor Claseprubart in Patients with Generalized Myasthenia Gravis 1.3 MB
Sustained Safety and Efficacy Profile of Active C1s Inhibitor Claseprubart in Patients with Generalized Myasthenia Gravis 1.3 MB
American Academy of Neurology (AAN) Autoimmune Neurology Conference August 7, 2026 Minimal Symptom Expression with Claseprubart, an Active C1s Inhibitor, in Patients with Generalized Myasthenia Gravis 2.7 MB
Minimal Symptom Expression with Claseprubart, an Active C1s Inhibitor, in Patients with Generalized Myasthenia Gravis 2.7 MB
American Academy of Neurology (AAN) Autoimmune Neurology Conference August 7, 2026 Safety and Efficacy of Claseprubart, an Active C1s Inhibitor, in Patients with Generalized Myasthenia Gravis 566.7 KB
Safety and Efficacy of Claseprubart, an Active C1s Inhibitor, in Patients with Generalized Myasthenia Gravis 566.7 KB
American Academy of Neurology (AAN) Autoimmune Neurology Conference August 7, 2026 Safety and Efficacy of Claseprubart, an Active C1s Inhibitor, in Patients with Generalized Myasthenia Gravis 2.3 MB
Safety and Efficacy of Claseprubart, an Active C1s Inhibitor, in Patients with Generalized Myasthenia Gravis 2.3 MB
American Academy of Neurology (AAN) Autoimmune Neurology Conference August 7, 2026 CAPTIVATE Trial Design: A Pivotal Phase 3 Study of Claseprubart in Chronic Inflammatory Demyelinating Polyneuropathy 2.3 MB
CAPTIVATE Trial Design: A Pivotal Phase 3 Study of Claseprubart in Chronic Inflammatory Demyelinating Polyneuropathy 2.3 MB
American Academy of Neurology (AAN) Autoimmune Neurology Conference August 7, 2026 Potential Mechanistic Advantages of aC1s Targeting in Myasthenia Gravis: Upstream Versus Downstream Complement Blockade 2.7 MB
Potential Mechanistic Advantages of aC1s Targeting in Myasthenia Gravis: Upstream Versus Downstream Complement Blockade 2.7 MB
